James Lucocq (@jameslucocq) 's Twitter Profile
James Lucocq

@jameslucocq

Surgical Registrar, BJS, BJS institute, RAMC, MFAC, MRBS Student, Medical Xcelerator

ID: 1212195520753438720

linkhttps://www.researchgate.net/profile/James-Lucocq calendar_today01-01-2020 02:15:20

29 Tweet

90 Followers

34 Following

Girivasan Muthukumarasamy (@giri_mks) 's Twitter Profile Photo

Patient with acute gallstone pancreatitis, unfit for GA/ Lap Chole. MRCP - small stones in GB but no CBD stone. Do you proceed with ERCP and prophylactic sphincterotomy? Is there evidence that prevents recurrent pancreatitis?

PAINAP STUDY (@painapstudy) 's Twitter Profile Photo

2100 patients with Acute Pancreatitis recruited into PAINAP study in 3 months !!! Potentially the largest study in literature dedicated to pain management in AP and very grateful to recruiting centers Recruitment now complete and moving onto data validation. Hpb North_Newcastle

2100 patients  with Acute Pancreatitis recruited into PAINAP study in 3 months  !!! 

Potentially the largest study in literature dedicated to pain management in AP and very grateful to recruiting centers 

Recruitment now complete and moving onto data validation. 

<a href="/hpbnorth/">Hpb North_Newcastle</a>
Ahmad Nassar (@ahmadnassar) 's Twitter Profile Photo

The value of Transvesical-assisted cystic pedicle dissection. A large stone appearing at ? Hartman Pouch, ? GB neck. 1- never dissect proximal to stone 2- never assume it is in HP 3- immediately suspect Mirizzi 4- accessing the stone through the GB will help either transvesical

Nigel B. Jamieson (@nigeljamieson) 's Twitter Profile Photo

Risk of Recurrence > Surgical Resection for Adenocarcinoma Arising from IPMN: International Multicentre Observational Study 18centres 459patients #pancreaticcancer ⁦Annals of Surgery⁩ ⁦Sanjay Pandanaboyana⁩ ⁦Kjetil Søreide⁩ ⁦Surgery Glasgow Royal Infirmary⁩ pubmed.ncbi.nlm.nih.gov/37873663/

Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

👉Recurrence patterns and Rx of Recurrence for Invasive #IPMN 🌏459patients 18 Pancreatic units ✅1y recurrence 23% Overall Recurrence 45% Median time to recurrence 33m ✅Adj chemo No impact on recurrence ✅Rx of recurrence⤴️survival Annals of Surgery shorturl.at/kwVZ2

👉Recurrence patterns and Rx of Recurrence for Invasive #IPMN
🌏459patients 18 Pancreatic units 
✅1y recurrence 23% Overall Recurrence 45%
 Median time to recurrence 33m
✅Adj chemo No impact on recurrence
✅Rx of recurrence⤴️survival 
<a href="/AnnalsofSurgery/">Annals of Surgery</a> shorturl.at/kwVZ2
Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

👉🏾Prospective study on PROMs and QOL after PD at 5 time points 👉🏾Adj Chemo and post-op complications did not affect QoL 👉🏾General QoL and health were PROMs rated as ‘very important' 👉🏾QoL measures return to baseline at 6-months postop @HPBjournal shorturl.at/amE04

👉🏾Prospective  study on PROMs and QOL after PD at 5 time points 
👉🏾Adj Chemo  and  post-op complications did not affect QoL
👉🏾General QoL and health were PROMs rated as ‘very important'
👉🏾QoL measures return to baseline at 6-months postop
<a href="/hpbjournal/">@HPBjournal</a> shorturl.at/amE04
Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

➡️Long term outcomes PDAC versus A-IPMN ➡️18 centres 476 PDAC vs 459 A-IPMN patients ➡️Median survival Survival PDAC 19m vs 39 m ⏱️to recurrence for 15 vs 33 m 📈10 y survival 9% vs 34% ➡️Adj Chemo⬆️survival PDAC. No impact A-IPMN tinyurl.com/2ych76r7@Annal…

➡️Long term outcomes PDAC versus A-IPMN
➡️18  centres 476 PDAC vs 459 A-IPMN patients
➡️Median survival Survival PDAC  19m vs 39 m
⏱️to recurrence for 15 vs 33 m
📈10 y survival 9% vs 34%
➡️Adj Chemo⬆️survival PDAC. No impact A-IPMN
tinyurl.com/2ych76r7@Annal…
Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

🌎Multicenter study on Adj chemo (AC) 💊 for adenocarcinoma in IPMN 👉 18 centers & 469 patients 60% ✅AC 👉 78 m follow up 👎AC no impact on recurrence DFS OS 👎 No benefit in high risk groups 💊 No chemo regimen superior James Lucocq BJS tinyurl.com/39yr3b85

🌎Multicenter study on Adj chemo (AC) 💊 for adenocarcinoma in  IPMN
👉 18 centers &amp; 469 patients 60% ✅AC 
👉 78 m follow up 
👎AC no impact on  recurrence DFS OS
👎 No benefit in high risk groups
 💊 No chemo regimen superior
<a href="/jameslucocq/">James Lucocq</a> <a href="/BJSurgery/">BJS</a> 
tinyurl.com/39yr3b85
Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

Great to see James Lucocq and Nejo Joseph give their oral presentations at IHPBA Cape Town including one in best of the best section. Thanks again to all collaborators for the data #ipmn #adenoipmn #collaborative

Great to see <a href="/jameslucocq/">James Lucocq</a> and <a href="/joseph_nejo/">Nejo Joseph</a> give their oral presentations at <a href="/IHPBA/">IHPBA</a> Cape Town  including one in best of the best section. 
Thanks again to all collaborators for the data 
#ipmn #adenoipmn 
#collaborative
Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

Multicenter study🌎on Long term survival after 🗡️ malignant IPMN 👉288 pts 98 m FU 👉48% recurrence with⬆️systemic recurrence 👉5y OS 46% 👉5y DFS 35% 👉Multivisceral resection, tail location , LVI, PNI⬇️long-term DFS James Lucocq SURGERY Journal tinyurl.com/2rx8aeuy

Multicenter study🌎on Long term survival after 🗡️ malignant IPMN
👉288 pts 98 m  FU
👉48% recurrence with⬆️systemic recurrence
👉5y OS 46%
👉5y DFS 35%
👉Multivisceral resection, tail location , LVI, 
       PNI⬇️long-term DFS <a href="/jameslucocq/">James Lucocq</a>  <a href="/SurgJournal/">SURGERY Journal</a> tinyurl.com/2rx8aeuy
Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

👉🌎study on Precursor Epithelial types of MalignantIPMN and recurrence/survival after🗡️ 297 🧑‍🤝‍🧑 👉 Gastric, PB, mixed🧑‍🤝‍🧑same clinicopath but ⬇️outcomes than intestinal 👉⏰to recurrence👍intestinal type 👉 Adj chemo⬆️survival in PB type shorturl.at/zcKCx James Lucocq

👉🌎study on Precursor Epithelial types of MalignantIPMN and recurrence/survival after🗡️ 
297 🧑‍🤝‍🧑
👉   Gastric, PB, mixed🧑‍🤝‍🧑same clinicopath  but  ⬇️outcomes than intestinal
👉⏰to recurrence👍intestinal type
👉  Adj chemo⬆️survival in PB type
shorturl.at/zcKCx <a href="/jameslucocq/">James Lucocq</a>
Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

👉🌎 on analgesic use in AP shorturl.at/6Za9l👉 1864 🧑‍🤝‍🧑 118 centres & 27 countries 👉 Opioid use⬇️in Europe and ⬆️ Asia and AUS 👉 Pain severity, long pain duration, ANC, WON ⬆️ opioid use at discharge my_UEG guidelines ✍️ underway shorturl.at/boe1W Cecilie Siggaard Knoph

👉🌎  on analgesic use in AP shorturl.at/6Za9l👉 1864 🧑‍🤝‍🧑 118 centres &amp; 27 countries
👉 Opioid use⬇️in Europe and ⬆️ Asia  and AUS
👉 Pain severity, long pain duration, ANC, WON  ⬆️ opioid use at discharge
<a href="/my_ueg/">my_UEG</a>  guidelines ✍️ underway shorturl.at/boe1W
<a href="/CSKnoph/">Cecilie Siggaard Knoph</a>
Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

#Editorial BJS on Adenoca arising from IPMN #AIPMN study 459🧑🏻‍🤝‍🧑🏻 👉 5y DFS 30% 👉Rx of recurrence ⬆️ Survival 👉AdjChemo⛔impact 👉Gastric/PBtypes⬇️prognosis 👉Survival related to invasive type than precursor 👉10y OS A-IPMN 35% PDAC 9% James Lucocq tinyurl.com/mwdceups

#Editorial <a href="/BJSurgery/">BJS</a> on Adenoca arising from IPMN #AIPMN study 459🧑🏻‍🤝‍🧑🏻
👉 5y DFS 30%
👉Rx of recurrence ⬆️ Survival
👉AdjChemo⛔impact
👉Gastric/PBtypes⬇️prognosis
👉Survival related to invasive type than precursor
👉10y OS A-IPMN 35% PDAC 9%
 <a href="/jameslucocq/">James Lucocq</a> tinyurl.com/mwdceups
E-AHPBA (@eahpba) 's Twitter Profile Photo

The E-AHPBA Scientific & Research Committee is pleased to endorse the ADENO-IPMN 2 Study with a Blue Seal of Approval! 💙 Register your centre's participation here: shorturl.at/E5JKi Sanjay Pandanaboyana James Lucocq #EAHPBA #ScientificResearch #IPMN #Adenocarcinoma

Artur Zanellato (@arturzanellato) 's Twitter Profile Photo

School of Surgery at RCSEd this year was magnificent. Well done all Surgical Trainees who presented a really exciting research Morven Allan Leo Brown Duncan Rutherford JOE NORTON ALEX WALKER Kenneth McLean James Lucocq Lachlan Dick Katie Connor also known by Susan Boyle🤣

Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

🔪 Open 🔦 Laparoscopic 🤖 Robot Pancreatoduodenectomy Randomised Controlled Trials 🧮 Network Meta-Analysis on 7 RCT 1.3 K patients 🔦 LPD ⬇️ LOS and blood loss vs. OPD 🔪 OPD ⬇️ OR time vs. LPD 🤖 RPD similar OPD but data preliminary.. 🫵 Surprised? journals.lww.com/aosopen/fullte…

🔪 Open 🔦 Laparoscopic 🤖 Robot Pancreatoduodenectomy Randomised Controlled Trials

🧮 Network Meta-Analysis on 7 RCT 1.3 K patients

🔦 LPD ⬇️ LOS and blood loss vs. OPD
🔪 OPD ⬇️ OR time vs. LPD

🤖 RPD similar OPD but data preliminary..

🫵 Surprised?

journals.lww.com/aosopen/fullte…
Sanjay Pandanaboyana (@sanjay_hpb) 's Twitter Profile Photo

Epidemiological data on Acute Pancreatitis admissions (2013-2023) in England 🏴󠁧󠁢󠁥󠁮󠁧󠁿 @HPBjournal ➡️Incidence of AP 456 cases/mill ➡️Annual increase of 2.6 % ⬆️ ➡️ITU Admission 8% ➡️In-hospital mortality 4.5% ➡️ OS at 1, 5,10 y :88%,75% 63% ➡️ Northeast England ⬆️ James Lucocq

Epidemiological data on Acute Pancreatitis admissions  (2013-2023) in England 🏴󠁧󠁢󠁥󠁮󠁧󠁿 <a href="/hpbjournal/">@HPBjournal</a> 
➡️Incidence of AP 456 cases/mill
➡️Annual increase of 2.6 % ⬆️
➡️ITU Admission  8%
➡️In-hospital mortality 4.5%
➡️ OS at 1, 5,10 y :88%,75% 63% 
➡️ Northeast England ⬆️ 
<a href="/jameslucocq/">James Lucocq</a>